Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5060922 | 1.00 | BACE1 (0.81) | BACE1CTSD | |
| SCHEMBL5060953 | 0.96 | BACE1 (0.81) | BACE1CTSD | |
| SCHEMBL5060954 | 0.96 | BACE1 (0.81) | BACE1CTSD | |
| SCHEMBL5053206 | 0.90 | BACE1 (0.81) | BACE1CTSD | |
| SCHEMBL5743143 | 0.90 | BACE1 (0.81) | BACE1CTSD | |
| SCHEMBL5053211 | 0.90 | BACE1 (0.81) | BACE1CTSD | |
| SCHEMBL3181718 | 0.90 | BACE1 (1.00) | BACE1CTSD | |
| SCHEMBL3181724 | 0.90 | BACE1 (1.00) | BACE1CTSD | |
| SCHEMBL8281564 | 0.88 | BACE1 (0.84) | BACE1CTSD | |
| SCHEMBL5060912 | 0.88 | BACE1 (0.64) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249139-A1 | Benzamide 2-hydroxy-3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. | 2008-10-09 | — | — | US | claimed |
| US-20050032848-A1 | Administering enzyme inhibitors of beta secretase, an enzyme responsible for the production of amyloid beta peptide by mediating the cleavage of amyloid precursor proteins; Alzheimer's disease; cognition activators; Down's syndrome; neurodegenerative diseases; other dementias of mixed origins | ELAN PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | claimed |
| US-20080249139-A1 | Benzamide 2-hydroxy-3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249139-A1 | Benzamide 2-hydroxy-3-diaminoalkanes | BACE2, BACE1, APP | BACE1 2/4885CTSD 153/4885 |
| US-20050032848-A1 | Administering enzyme inhibitors of beta secretase, an enzyme responsible for the production of amyloid beta peptide by mediating the cleavage of amyloid precursor proteins; Alzheimer's disease; cognition activators; Down's syndrome; neurodegenerative diseases; other dementias of mixed origins | BACE1, BACE2, APP | BACE1 1/4885CTSD 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.